Literature DB >> 7533260

Induction of estrogen independence of ZR-75-1 human breast cancer cells by epigenetic alterations.

T van Agthoven1, T L van Agthoven, A Dekker, J A Foekens, L C Dorssers.   

Abstract

Antagonists of steroid hormones are clinically important in the management of breast cancer. However, the duration of response is limited due to the development of hormone-independent tumors in virtually all cases. In an attempt to obtain insight into the mechanisms underlying antiestrogen resistance, the consequences of epigenetic changes in gene expression were studied in vitro. Estrogen-dependent ZR-75-1 human breast cancer cells were treated with 5-azacytidine, an inhibitor of DNA methylation, and cultured in the absence of estradiol or in the presence of antiestrogens. Estrogen-independent cell colonies developed within 3 weeks at high frequency in 5-azacytidine-treated cultures (0.7 x 10(-3), in contrast to control cultures (< or = 10(-8). The derived cells (ZR/AZA) were resistant to 4-hydroxytamoxifen and ICI 164,384, independent of the selection protocol, but had lost the ability to grow anchorage-independent. Whereas expression of estrogen receptor, progesterone receptor, and pS2 were down-regulated, expression of epidermal growth factor (EGF) receptor and HER2/neu were increased in ZR/AZA cells. In contrast to the stable altered expression patterns of estrogen receptor and EGF receptor, transient keratin 7 expression was observed. Transforming growth factor-alpha mRNA was identified in ZR-75-1 cells and ZR/AZA cells and EGF-like peptides were secreted in the culture medium. Proliferation of ZR/AZA cells could be partially inhibited with an EGF receptor-blocking antibody. Presence of both growth factor receptors and possible ligands suggests the development of an autocrine growth mechanism. Our data show that epigenetic alterations of gene expression result in rapid progression of breast cancer cells to hormone independence.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7533260     DOI: 10.1210/mend.8.11.7533260

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  15 in total

Review 1.  Growth factor signalling in endocrine and anti-growth factor resistant breast cancer.

Authors:  R I Nicholson; I R Hutcheson; H E Jones; S E Hiscox; M Giles; K M Taylor; J M W Gee
Journal:  Rev Endocr Metab Disord       Date:  2007-09       Impact factor: 6.514

2.  Identification of BCAR3 by a random search for genes involved in antiestrogen resistance of human breast cancer cells.

Authors:  T van Agthoven; T L van Agthoven; A Dekker; P J van der Spek; L Vreede; L C Dorssers
Journal:  EMBO J       Date:  1998-05-15       Impact factor: 11.598

3.  Association of pS2 (TFF1) release with breast tumour proliferative rate: in vitro and in vivo studies.

Authors:  S J Reshkin; T Tedone; M Correale; A Mangia; V Casavola; A Paradiso
Journal:  Cell Prolif       Date:  1999 Apr-Jun       Impact factor: 6.831

4.  Expression and relevance of TRPS-1: a new GATA transcription factor in breast cancer.

Authors:  Jie Qing Chen; Yi Bao; Jennifer Litton; Li Xiao; Hua-Zhong Zhang; Carla L Warneke; Yun Wu; Xiaoyun Shen; Sheng Wu; Ruth L Katz; Aysegul Sahin; Melissa Bondy; James L Murray; Laszlo Radvanyi
Journal:  Horm Cancer       Date:  2011-04       Impact factor: 3.869

Review 5.  Tamoxifen resistance in breast cancer: elucidating mechanisms.

Authors:  L C Dorssers; S Van der Flier; A Brinkman; T van Agthoven; J Veldscholte; E M Berns; J G Klijn; L V Beex; J A Foekens
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 6.  Tamoxifen resistance and epigenetic modifications in breast cancer cell lines.

Authors:  Eric Badia; Joan Oliva; Patrick Balaguer; Vincent Cavaillès
Journal:  Curr Med Chem       Date:  2007       Impact factor: 4.530

7.  Models and Mechanisms of Acquired Antihormone Resistance in Breast Cancer: Significant Clinical Progress Despite Limitations.

Authors:  Elizabeth E Sweeney; Russell E McDaniel; Philipp Y Maximov; Ping Fan; V Craig Jordan
Journal:  Horm Mol Biol Clin Investig       Date:  2012-02

8.  BCAR4 induces antioestrogen resistance but sensitises breast cancer to lapatinib.

Authors:  M F E Godinho; J D Wulfkuhle; M P Look; A M Sieuwerts; S Sleijfer; J A Foekens; E F Petricoin; L C J Dorssers; T van Agthoven
Journal:  Br J Cancer       Date:  2012-08-14       Impact factor: 7.640

9.  Tamoxifen-induced epigenetic silencing of oestrogen-regulated genes in anti-hormone resistant breast cancer.

Authors:  Andrew Stone; Fatima Valdés-Mora; Julia M W Gee; Lynne Farrow; Richard A McClelland; Heidi Fiegl; Carol Dutkowski; Rachael A McCloy; Robert L Sutherland; Elizabeth A Musgrove; Robert I Nicholson
Journal:  PLoS One       Date:  2012-07-10       Impact factor: 3.240

10.  Breast cancer oestrogen independence mediated by BCAR1 or BCAR3 genes is transmitted through mechanisms distinct from the oestrogen receptor signalling pathway or the epidermal growth factor receptor signalling pathway.

Authors:  Lambert C J Dorssers; Ton van Agthoven; Arend Brinkman; Jos Veldscholte; Marcel Smid; Koen J Dechering
Journal:  Breast Cancer Res       Date:  2004-11-16       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.